Recombinant M. bovis BCG expressing the PLD protein promotes survival in mice challenged with a C. pseudotuberculosis virulent strain

Karen Silva Leal; Mara Thais de Oliveira Silva; Andréa de Fátima Silva Rezende; Francisco Silvestre Brilhante Bezerra; Karine Begnini; Fabiana Seixas; Tiago Collares; Odir Dellagostin; Ricardo Wagner Portela; Vasco Ariston de Carvalho Azevedo; Sibele Borsuk

doi:10.1016/j.vaccine.2018.05.049

Recombinant M. bovis BCG expressing the PLD protein promotes survival in mice challenged with a C. pseudotuberculosis virulent strain

Vaccine. 2018 Jun 14;36(25):3578-3583. doi: 10.1016/j.vaccine.2018.05.049.

Affiliations

¹ Laboratório de Biotecnologia Infecto-Parasitária, Centro de Desenvolvimento Tecnológico, Biotecnologia, UFPel, Pelotas, RS 96010-900, Brazil. Electronic address: [email protected].
² Laboratório de Biotecnologia Infecto-Parasitária, Centro de Desenvolvimento Tecnológico, Biotecnologia, UFPel, Pelotas, RS 96010-900, Brazil.
³ Laboratório de Biotecnologia do Câncer, Centro de Desenvolvimento Tecnológico, Biotecnologia, UFPel, Pelotas, RS 96010-900, Brazil.
⁴ Laboratório de Vacinologia, Centro de Desenvolvimento Tecnológico, Biotecnologia, UFPel, Pelotas, RS 96010-900, Brazil.
⁵ Laboratório de Imunologia e Biologia Molecular, Instituto de Ciências da Saúde, UFBA, Salvador, BA 40140-100, Brazil.
⁶ Laboratório de Genética Celular e Molecular, Instituto de Ciências Biológicas, UFMG, Belo Horizonte, MG 31270-901, Brazil.

PMID: 29759378
DOI: 10.1016/j.vaccine.2018.05.049

Abstract

The aim of this study was to evaluate the survival of mice inoculated with M. bovis BCG Pasteur recombinant expressing the PLD protein and challenged with a C. pseudotuberculosis virulent strain. Four groups were immunized with a sterile 0.9% saline solution (G1), 10⁶ CFU of M. bovis BCG Pasteur (G2), 10⁶ CFU of M. bovis BCG/pld (G3) or 10⁶ CFU of M. bovis BCG/pld with a booster with rPLD (G4) and challenged with 10⁴ CFU of C. pseudotuberculosis MIC-6 strain. The highest survival rate of 88% was observed in G4, followed by 77% in G3 and 66% in G2. A significant statistical difference was observed in the levels of cytokines IFN-γ and IL-10 in vaccinated groups (G3 and G4) when compared with the control group (G1) (p < 0.05). The results seem promising as the recombinant vaccine elicited a cellular immune response and provided significant survival after a high virulent challenge.

Keywords: Caseous lymphadenitis; Phospholipase D; Recombinant M. bovis BCG.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Animals
BCG Vaccine / administration & dosage
BCG Vaccine / genetics*
BCG Vaccine / immunology
Bacterial Proteins / genetics
Bacterial Proteins / immunology*
Cloning, Molecular
Corynebacterium Infections / immunology
Corynebacterium Infections / microbiology
Corynebacterium Infections / mortality
Corynebacterium Infections / prevention & control*
Corynebacterium pseudotuberculosis / immunology
Corynebacterium pseudotuberculosis / pathogenicity
Escherichia coli / genetics
Escherichia coli / metabolism
Gene Expression
Genetic Engineering
Genetic Vectors / chemistry
Genetic Vectors / metabolism
Immunization, Secondary
Mice
Mice, Inbred BALB C
Mycobacterium bovis / genetics
Mycobacterium bovis / immunology
Phospholipase D / genetics
Phospholipase D / immunology*
Recombinant Proteins / genetics
Recombinant Proteins / immunology
Survival Analysis
Vaccination / methods*

Substances

BCG Vaccine
Bacterial Proteins
Recombinant Proteins
Phospholipase D